These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28650720)

  • 1. Nonclinical Development of ENV905 (Difluprednate) Ophthalmic Implant for the Treatment of Inflammation and Pain Associated with Ocular Surgery.
    Verhoeven RS; Garcia A; Robeson R; Gilger BC; Culp D; Struble C; Hamm L; Navratil T; Yerxa B
    J Ocul Pharmacol Ther; 2018; 34(1-2):161-169. PubMed ID: 28650720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay.
    Tajika T; Waki M; Tsuzuki M; Kida T; Sakaki H
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):29-34. PubMed ID: 21182429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
    Korenfeld MS; Silverstein SM; Cooke DL; Vogel R; Crockett RS;
    J Cataract Refract Surg; 2009 Jan; 35(1):26-34. PubMed ID: 19101421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits.
    Tajika T; Isowaki A; Sakaki H
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):43-9. PubMed ID: 21118027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
    Wilson ME; O'Halloran H; VanderVeen D; Roarty J; Plager DA; Markwardt K; Gedif K; Lambert SR
    Eye (Lond); 2016 Sep; 30(9):1187-94. PubMed ID: 27367745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difluprednate-Hydroxypropyl-β-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model.
    Shelley H; Annaji M; Smith FT; Babu RJ
    J Ocul Pharmacol Ther; 2022; 38(1):92-101. PubMed ID: 34665027
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery.
    Abessi B; Brooksby L; Schultze RL
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S37-S42. PubMed ID: 28628490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis.
    Foster CS; Davanzo R; Flynn TE; McLeod K; Vogel R; Crockett RS
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):475-83. PubMed ID: 20809807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion.
    Tajika T; Takahashi H; Sakai Y; Fujii H; Isowaki A; Sakaki H
    Xenobiotica; 2010 Aug; 40(8):569-77. PubMed ID: 20509750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery.
    Smith S; Lorenz D; Peace J; McLeod K; Crockett RS; Vogel R
    Clin Ophthalmol; 2010 Sep; 4():983-91. PubMed ID: 20856594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and potential complications of difluprednate use for pediatric uveitis.
    Slabaugh MA; Herlihy E; Ongchin S; van Gelder RN
    Am J Ophthalmol; 2012 May; 153(5):932-8. PubMed ID: 22265149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension.
    Tijunelis MA; Person E; Niziol LM; Musch DC; Ernest P; McBain M; Mian SI
    J Cataract Refract Surg; 2017 Feb; 43(2):223-227. PubMed ID: 28366370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®).
    Quantz K; Anderson AL; Harman CD; Noland EL; Del Valle JM; Occelli LM; Burn JB; Petersen-Jones SM; Langlois DK; Pirie CG; Petersen AD; Komáromy AM
    BMC Vet Res; 2021 Dec; 17(1):366. PubMed ID: 34847929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difluprednate for inflammatory eye disorders.
    Mulki L; Foster CS
    Drugs Today (Barc); 2011 May; 47(5):327-33. PubMed ID: 22013563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate.
    Yamaguchi M; Yasueda S; Isowaki A; Yamamoto M; Kimura M; Inada K; Ohtori A
    Int J Pharm; 2005 Sep; 301(1-2):121-8. PubMed ID: 16023810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery.
    Donnenfeld ED; Holland EJ; Solomon KD; Fiore J; Gobbo A; Prince J; Sandoval HP; Shull ER; Perry HD
    Am J Ophthalmol; 2011 Oct; 152(4):609-617.e1. PubMed ID: 21704965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 0.05% Difluprednate Ophthalmic Emulsion on Proinflammatory Cytokine Levels After Retinal Laser Photocoagulation in Rabbits.
    Kakimoto H; Takamura Y; Arimura S; Miyake S; Matsumura T; Gozawa M; Iwasaki K; Morioka M; Yamada Y; Inatani M
    J Ocul Pharmacol Ther; 2018 Jun; 34(5):410-415. PubMed ID: 29812993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of early posttreatment effects of two steroidal anti-inflammatory ophthalmic drugs on the ocular inflammatory response induced by paracentesis in healthy canine eyes.
    Sato K; Iwasaki K; Nagai N; Yamashita Y; Chikazawa S; Hoshi F; Kanai K
    Vet Ophthalmol; 2019 Sep; 22(5):607-613. PubMed ID: 30716193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparative Preclinical Evaluation of a Novel Difluprednate 0.04% BID Ophthalmic Solution and Marketed 0.05% QID Ophthalmic Emulsion.
    Khopade AJ; Halder A; Patel V; Shah H; Shah A; Burade V; Zalawadia R; Patel A; Awati C; Zope M
    J Ocul Pharmacol Ther; 2024; 40(1):57-66. PubMed ID: 37922455
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India.
    Vidyadevi M; Anuradha A; Rashmi G; Shilpa R; Nishath S
    Nepal J Ophthalmol; 2017 Jan; 9(18):24-29. PubMed ID: 29022951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.